UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 585

Sortiert nach

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

The oncologist (Dayton, Ohio), 2015-06, Vol.20 (6), p.660-673

2015

Link zum Volltext

Verfügbarkeit prüfen

Current Diagnosis and Management of Small-Cell Lung Cancer

Mayo Clinic proceedings, 2019-08, Vol.94 (8), p.1599-1622

2019

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Journal of thoracic oncology, 2020-08, Vol.15 (8), p.1281-1297

2020

Link zum Volltext

Verfügbarkeit prüfen

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Cancer treatment reviews, 2014-09, Vol.40 (8), p.917-926

2014

Link zum Volltext

Verfügbarkeit prüfen

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Clinical cancer research, 2008-01, Vol.14 (2), p.342-346

2008

Link zum Volltext

Verfügbarkeit prüfen

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2048-2050

2016

Link zum Volltext

Verfügbarkeit prüfen

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1396-1403

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Link zum Volltext

Verfügbarkeit prüfen

ALK inhibitors in the treatment of advanced NSCLC

Cancer treatment reviews, 2014-03, Vol.40 (2), p.300-306

2014

Link zum Volltext

Verfügbarkeit prüfen

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

The lancet oncology, 2019-08, Vol.20 (8), p.1098-1108

2019

Link zum Volltext

Verfügbarkeit prüfen

Small Cell Lung Cancer

Mayo Clinic proceedings, 2008-03, Vol.83 (3), p.355-367

2008

Link zum Volltext

Verfügbarkeit prüfen

KRAS: From undruggable to a druggable Cancer Target

Cancer treatment reviews, 2020-09, Vol.89, p.102070-102070, Article 102070

2020

Link zum Volltext

Verfügbarkeit prüfen

Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

PloS one, 2021-12, Vol.16 (12), p.e0261478-e0261478

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2139-2146

2008

Link zum Volltext

Verfügbarkeit prüfen

Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5386-5403

2005

Link zum Volltext

Verfügbarkeit prüfen

The clinical development of MEK inhibitors

Nature reviews. Clinical oncology, 2014-07, Vol.11 (7), p.385-400

2014

Link zum Volltext

Verfügbarkeit prüfen

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Science translational medicine, 2016-02, Vol.8 (324), p.324ra14

2016

Link zum Volltext

Verfügbarkeit prüfen

Early Clinical Development of ARQ 197, a Selective, Non–ATP‐Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

The oncologist (Dayton, Ohio), 2011-06, Vol.16 (6), p.788-799

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

Frontiers in oncology, 2022-08, Vol.12, p.955440-955440

2022

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

Clinical cancer research, 2004-06, Vol.10 (12), p.4276s-4280s

ADJEI, Alex A

2004

Link zum Volltext

Verfügbarkeit prüfen

Our Work Is Done, and You Are in Good Hands

JTO clinical and research reports, 2023-01, Vol.4 (1), p.100447-100447, Article 100447

Adjei, Alex A.

2023

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.96-102

2019

Link zum Volltext

Verfügbarkeit prüfen

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

Carcinogenesis (New York), 2012-07, Vol.33 (7), p.1270-1276

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 585

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(556)
Mit Volltextzugriff
(552)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(338)
Life Sciences & Biomedicine
(329)
Humans
(308)
Oncology
(287)
Female
(142)
Male
(135)
Biological And Medical Sciences
(125)
Aged
(124)
Medical Sciences
(124)
Middle Aged
(123)
Adult
(96)
Tumors
(83)
Respiratory System
(81)
Lung Neoplasms - Drug Therapy
(78)
Neoplasms - Drug Therapy
(78)
Antineoplastic Agents
(76)
Pharmacology. Drug Treatments
(75)
Aged, 80 And Over
(66)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(66)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(61)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Thoracic Oncology
(95)
Journal Of Clinical Oncology
(85)
Clinical Cancer Research
(36)
Cancer Research
(22)
Clinical Lung Cancer
(21)
Investigational New Drugs
(20)
Cancer
(17)
Plos One
(14)
Molecular Cancer Therapeutics
(12)
Cancer Chemotherapy And Pharmacology
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

Current Diagnosis and Management of Small-Cell Lung Cancer

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

ALK inhibitors in the treatment of advanced NSCLC

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

Small Cell Lung Cancer

KRAS: From undruggable to a druggable Cancer Target

Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy

The clinical development of MEK inhibitors

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Early Clinical Development of ARQ 197, a Selective, Non–ATP‐Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

Our Work Is Done, and You Are in Good Hands

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

Suchergebnisse filtern